Takeda has decided that there is a future for its aurora kinase A inhibitor alisertib after it failed a phase 3 trial in lymphoma – but the company won't be taking the drug forward itself.<
The venture capital arm of the UK’s biggest insurance firm Aviva is to invest $5 million (£4m) in Owlstone Medical, one of the country’s most promising and potentially groundbreaking diagno
Two weeks after Amgen reported the top-line result of its CodeBreak-200 trial of Lumakras in lung cancer, the data has been presented in abstract form at ESMO, showing a 34% improvement in
Medical imaging specialist Median Technologies has launched a new business unit that will provide decision-making tools – underpinned by artificial intelligence – for sponsors of clinical t
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.